April 16, 2013 Naysayers may harp on the low market valuations of stem cell companies, but Geoff MacKay has an insider's perspective.
http://www.investorideas.com/news/2013/biotech/04161.asp
http://www.investorideas.com/news/2013/biotech/04161.asp
No comments:
Post a Comment